Factors influencing venetoclax resistance time and coping strategies

Venetoclax (Venetoclax), an anti-cancer drug targeting the BCL-2 protein, has shown significant efficacy in the treatment of chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). However, as treatment progresses, the emergence of drug resistance becomes a major challenge that affects the effectiveness of treatment. The length of drug resistance varies depending on individual patient differences, disease type and disease progression.

The resistance to venetoclax is mainly due to the variation of BCL-2 protein inside cancer cells, gene mutations and changes in the tumor microenvironment. In some patients, cancer cells may weaken the therapeutic effect of venetoclax by enhancing the expression of other anti-apoptotic proteins (such as MCL-1, BFL-1, etc.). At the same time, genetic mutations (such as TP53 mutations) may also lead to reduced drug efficacy.

Research points out that most CLL patients respond well initially after receiving venetoclax treatment, but drug resistance often occurs between 6 months and 2 years. The arrival of this time point is affected by multiple factors such as the patient's age, underlying health status, tumor burden, previous treatment response, and whether other drugs are used in combination.

In the face of drug resistance, doctors need to flexibly adjust treatment plans. For CLLresistant patients, the introduction of BTK inhibitors (such as ibrutinib) or chemotherapy regimens may be considered. In addition, genetic testing for drug-resistant tumors can help doctors develop more personalized treatment strategies for patients.

During treatment, regular follow-up and monitoring are crucial to detect signs of drug resistance in a timely manner. Doctors should closely observe the patient's treatment response through blood tests and clinical evaluation, and promptly adjust the treatment plan according to the actual situation to ensure the effectiveness of the treatment.